Omega Fund Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Omega Fund Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-167,157	Closed	-$2.45M	–	17
2019 Q1	$2.45M	Hold	167,157	–	–	0.79%	12
2018 Q4	$1.79M	Sell	167,157 -56,300	-25%	-$740K	1.32%	11
2018 Q3	$3.41M	Hold	223,457	–	–	1.61%	12
2018 Q2	$2.74M	Hold	223,457	–	–	2.02%	12
2018 Q1	$2.14M	Hold	223,457	–	–	2.1%	9
2017 Q4	$2.02M	Hold	223,457	–	–	1.46%	11
2017 Q3	$1.28M	Hold	223,457	–	–	0.73%	10
2017 Q2	$708K	Hold	223,457	–	–	0.44%	11
2017 Q1	$760K	Hold	223,457	–	–	0.49%	11
2016 Q4	$644K	Hold	223,457	–	–	0.52%	10
2016 Q3	$1.31M	Hold	223,457	–	–	1%	9
2016 Q2	$670K	Hold	223,457	–	–	0.5%	11
2016 Q1	$1.2M	Hold	223,457	–	–	0.83%	10
2015 Q4	$2.65M	Hold	223,457	–	–	1.48%	9
2015 Q3	$1.83M	Hold	223,457	–	–	1.03%	9
2015 Q2	$3.12M	Sell	223,457 -136,990	-38%	-$2.51M	1.57%	6
2015 Q1	$8.66M	Sell	360,447 -108,024	-23%	-$2.43M	3.75%	5
2014 Q4	$7.72M	Buy	+468,471	New	+$5.41M	3.55%	6

Other funds holding DRNA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Omega Fund Management's DRNA Position: Q2 2019 in Review

Omega Fund Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q2 2019, closing a stake of 167,157 shares — an estimated $2.45M sold.

Omega Fund Management first reported a position in DRNA in Q4 2014 and held it in 18 quarters. The position peaked at $8.66M in Q1 2015. 98 funds tracked by Wall St. Rank hold DRNA as of Q2 2019.

Omega Fund Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Omega Fund Management sold 167,157 Dicerna Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2.45M.
Omega Fund Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2014 and held it in 18 quarters.
Omega Fund Management's Dicerna Pharmaceuticals, Inc. position peaked at $8.66M in Q1 2015.
98 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q2 2019.

Based on Omega Fund Management's 13F filing for Q2 2019, filed 13 Aug 2019.